Shares of Sellas Life Sciences (SLS) slid 10.1% to $10.18 on Monday as investors bailed out amid growing unease that top-line data from the company's make-or-break Phase 3 cancer trial may take longer than expected. The sell-off marks the latest whipsaw in a stock that has been driven as much by social-media momentum as by clinical milestones — and it forces a hard question: Is the market misreading its own fear?
Two Missing Deaths Stand Between Sellas and Its Biggest Moment
The pivotal Phase 3 REGAL trial of GPS has reached 78 of 80 events, which will trigger final analysis at the 80th event. That was the count as of May 11. The trial requires 80 events (deaths) to trigger the event-driven final overall survival analysis. More than two months later, no announcement of that 80th event has come, and the silence is unnerving traders who had priced in a mid-2026 readout. The entire company valuation rests on whether its cancer vaccine extends survival in blood-cancer patients who have run out of standard options.
Some Analysts Think Slower Deaths Are a Bullish Signal Here's the paradox: analysts view the slower pace of required deaths in REGAL as a constructive sign that patients on Galinpepimut-S may be living longer than those on best available therapy.
Alliance Global raised its price target on Sellas to $25 from $10 and reaffirmed a Buy rating.
The average 12-month price target is $27.50, with two analysts recommending Buy and zero recommending Sell. That implies roughly 170% upside from today's price — if the data cooperate.
Cash Isn't the Problem; Patience Is
Q1 research and development expenses were $5.1M, general and administrative expenses were $4.1M, and cash and equivalents were $107.1M plus $7.5M from warrant exercises. With only $8.4M in quarterly net losses, Sellas has years of runway — this is not a company about to run dry. But recent price action highlights intense volatility driven more by speculative trading than by changes in the core business, with traders navigating a classic momentum boom-and-bust pattern.
Over the past 52 weeks, SLS has swung between a high of $15.88 and a low of $1.39.
The Bottom Line for Shareholders Sellas is a single-trial company approaching a binary verdict — either the vaccine works or it doesn't. Sellas will release its next earnings report on August 6, 2026 , which could provide a fresh event count. Until then, every silent day widens the gap between believers and sellers.